Comparing Behavioral Therapy With and Without GLP-1 Analogues for Adults Aged 18 to 65 With Severe Obesity and Binge Eating Disorder

What this Trial Is About

Researchers are investigating the effects of using GLP-1 analogues compared to not using appetite suppressants as part of a lifestyle treatment program for adults with both obesity and binge eating disorder BED. This prospective observational study aims to evaluate changes in BED symptoms over 12 months and to explore whether participants adopt other harmful coping strategies. The study also examines psychological well-being, weight changes, and their impact on obesity-related health conditions. Participants will be divided into two groups one group will receive standard lifestyle treatment including cognitive behavioral therapy-enhanced CBT-E group sessions and individual consultations every four months along with GLP-1 analogue medication prescribed by their physician. The other group will receive the same lifestyle treatment without any appetite-suppressing drugs. The GLP-1 analogues used may include liraglutide, semaglutide, or tirzepatide, with dosage and duration following routine clinical practice for at least 12 months. During the study, participants will attend 10 weekly CBT-E group therapy sessions and clinical consultations every four months. Evaluations will include patient questionnaires on BED symptoms and coping strategies, as well as measurements of weight and biochemical data at the start and after 12 months. Researchers will monitor changes in BED symptoms using the EDE-Q Global Score and track shifts in harmful coping mechanisms. The total study duration for participants is 12 months, with ongoing follow-up and data collection throughout this period.

Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity